Thursday, November 6, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Accenture A Lucrative Investment Over the Past Five Years

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Imagine if you had invested $100 in Accenture (NYSE: ACN) stock five years ago on March 13, 2019. Today, that investment would be worth $228.38, with ACN’s current price sitting at $378.32.

During this time period, Accenture has consistently outperformed the market, boasting an impressive average annual return of 17.99%. In fact, the compound annual total return to shareholders over the last five fiscal years was 16%, surpassing both the S&P 500 (11%) and the S&P 500 IT Sector Index (20%).

Not only has Accenture’s stock price seen significant growth, but the company has also achieved compound earnings per share (EPS) growth of approximately 14% per year. This showcases the remarkable performance and growth of Accenture in the market over the past five years.

ACN Stock Analysis: March 13, 2024 Update and Performance Overview

On March 13, 2024, ACN stock experienced a slight decrease in value, closing at $378.72. This represents a $1.76 drop from the previous market close, a decrease of 0.46%. Despite this drop, ACN is still trading near the top of its 52-week range and above its 200-day simple moving average.

The fact that ACN is trading near the top of its 52-week range indicates that the stock has been performing well over the past year. Additionally, trading above the 200-day simple moving average suggests that the stock is in an uptrend, further supporting the notion of a strong performance.

It is worth noting that ACN stock remained unchanged in after-hours trading, indicating that there was no significant movement in the stock price after the market closed. This could suggest that investors are holding onto their positions and waiting for more information before making any significant trades.

Overall, while ACN experienced a slight drop in value on March 13, 2024, the stock’s performance indicators suggest that it is still in a strong position. Investors may want to keep an eye on any future developments that could impact the stock’s performance.

ACN Stock Analysis: Revenue Holds Steady, Net Income and EPS Improve – What to Watch for in Future Quarters

ACN stock had a mixed performance on March 13, 2024, with total revenue holding flat since the last quarter, while net income and earnings per share showed significant improvements. Investors may want to closely monitor ACN’s financial performance in the upcoming quarters to assess the company’s overall growth and profitability.

Tags: ACN
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
The Rise of Strategic Partnerships in Life Sciences: Trends Shaping the Future of Healthcare Innovation

Investor Preview Kopin NASDAQ KOPN Quarterly Earnings Report Analysis

Energy Company Market Capitalization

EQT Corporation Faces Downgrade Despite Merger News

Technology Data analytics stock Trading

Microchip Technology A History of Strong Returns and Strategic Growth

Recommended

EEFT stock news

Analyst Ratings and Price Targets for Definitive Healthcare

2 years ago
Healthcare Services Stock Exchange

Analyst Ratings and Price Targets for Inari Medical NASDAQNARI

2 years ago
STZ stock news

Analyzing Analyst Recommendations and Target Price for FirstEnergy Corp.

2 years ago
Healthcare-sector

Introducing the Revolutionary Herbalife GLP1 Nutrition Companion

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

Is 3M’s Resurgence Signaling a Sustainable Recovery?

Eastman Chemical’s Challenging Quarter: A Deep Dive into the Numbers

BioNTech’s Crossroads: Navigating Losses Amid Cancer Research Promise

China Lifts Export Ban on Illumina’s DNA Sequencers, Sparking Market Rally

Trending

MannKind Stock
Analysis

MannKind Shares Surge on Exceptional Quarterly Performance

by Robert Sasse
November 6, 2025
0

MannKind Corporation witnessed a substantial rally in its share price following the release of its third-quarter 2025...

Amgen Stock

Amgen’s Impressive Quarterly Performance Fuels Investor Confidence

November 6, 2025
Teledyne Stock

An Overlooked AI Contender Emerges in Defense Technology

November 6, 2025
Molina Healthcare Stock

Molina Healthcare: Crisis or Opportunity as Legal Storms and a Legendary Investor Collide?

November 6, 2025
Nio Stock

Nio’s Unprecedented Delivery Streak Fuels Profitability Push

November 6, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • MannKind Shares Surge on Exceptional Quarterly Performance
  • Amgen’s Impressive Quarterly Performance Fuels Investor Confidence
  • An Overlooked AI Contender Emerges in Defense Technology

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com